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REPLY
We appreciate Drs. Bangalore and Messerli’s interest in our study
(1). In their letter to the editor they argue that our statement—“for
patients engaging in vigorous activities . . . -blockade-based ther-
apy can protect against excessive and repetitive elevations in blood
pressure (BP) which may occur during such activities”—may be
inappropriate because it is based on peripheral BP measurements.
They present evidence for greater risk of cardiovascular events or
lower-risk reduction with beta-blockers versus other antihyperten-
sive agents (2–4) and they suggest that this lower risk is due to
lower central BP achieved by antihypertensive agents other than
beta-blockers, as supported by the 4.3-mm Hg lower central BP
reported in the CAFÉ trial (4). Finally, they suggest that for
hypertensive patients “we do need a medication that curtails their
(central) BP rise but not one that curtails their activity.”
We agree that beta-blockers are not as effective in reducing
stroke rates when compared to other antihypertensive agents.
However, it is important to point out that there are no data on
therapies and outcomes in hypertensive patients with an exagger-
ated BP response to exercise.
Our statement is based on observations that the exercise BP on
those treated with beta-blockers was 14–19 mm Hg lower at
different workloads and for different antihypertensive agents. Most
will agree that the relationship between central and peripheral BP
is direct, and a change in one (central or peripheral) will result in
a proportional change in the same direction on the other. There-
fore, it is reasonable to assume that a peripheral exercise BP that is
14–19 mm Hg lower than the BP of those treated with antihy-
pertensive agents other than beta-blockers is more likely to reflect
a proportionally lower than higher central BP.
We also agree that beta-blockers reduce exercise time. The peak
exercise time in our patients on beta-blocker-based therapy was
lower by 19 s compared to the other agents. However, we are
confident that most health care providers and patients will gladly
trade 19-s reduction in peak exercise time for 19-mm Hg lower
systolic BP during physical activities.
*Peter F. Kokkinos, PhD
Steven Singh, MD
Puneet Narayan, MD
*Veterans Affairs Medical Center/Cardiology
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Standard Deviation of Sequential Five-
Minute R-R Interval Means (SDANN)
Is a Prognostic Marker, but Not
Necessarily an Autonomic Marker
The recent study by Fantoni et al. (1) provides strong data that
standard deviation of sequential 5-minute R-R interval means
(SDANN, a long-term measure of heart rate variability [HRV]) is
an important clinical tool. The researchers have convincingly
shown that 1) successful cardiac resynchronization therapy (CRT)
improved SDANN and 2) that an early improvement in SDANN
predicted a favorable long-term outcome.
The investigators interpret this increase in SDANN as reflecting
changes in autonomic tone, specifically modifications of the sympa-
thetic nervous system and parasympathetic nervous system interac-
tions in the heart. Although we agree that short-term measures of
HRV such as high-frequency (0.15 to 0.4 Hz) and low-frequency
(0.04 to 0.15 Hz) variability have been shown to be modulated by the
autonomic nervous system, there are no data showing that SDANN
is a reflection of the autonomic nervous system.
In contrast, we have shown that SDANN is heavily influenced by
physical activity. In an earlier study, the largest contributions to the
SDANN came around the transitions going into and waking from
sleep (2). We have also shown in both patients with heart failure and
in healthy subjects that SDANN significantly increased by changing
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